Genzyme sharpens diagnostic focus:
This article was originally published in Clinica
Executive Summary
Genzyme has continued refocusing its diagnostics business towards higher-value products by selling its bioreagent and ELISA immunochemistry lines to Alexon-Trend, a subsidiary of Sybron International. These product lines, which are supplied to diagnostics companies and OEM manufacturers, generated revenues of $3.1 million in 1998. Last year, Cambridge, Massachusetts-based Genzyme sold its research products business to Techne for $65 million. Financial terms of the latest transaction were not revealed. Separately, Milwaukee, Wisconsin-based Sybron's microbiology subsidiary, Remel, has acquired the assets of Micro Test, which manufactures transport media for infectious organisms.
You may also be interested in...
Novartis Draws Out Its APPLAUSE
Another data drop from Fabhalta’s IgAN trial looks encouraging, despite a missing abstract.
More Heartmate Troubles For Abbott. Latest Recall Includes 14 Deaths
Abbott initiated a recall in February of thousands of Heartmate devices due to a system obstruction that can result in serious health outcomes, including death. The FDA has now designated the recall as class I.
‘Unbalanced’ EU HTA Timelines Exacerbated By Rare Disease & Cancer Drugs
As it stands, drugmakers will have just 90 days to prepare their dossiers for EU-wide joint clinical assessments under the new Health Technology Assessment Regulation. Market access experts from EFPIA tell the Pink Sheet that this short deadline could delay patient access to complex medicines, such as innovative cancer drugs.